Enzon Pharmaceuticals, Inc. (ENZN) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Cranford, NJ, United States. El CEO actual es Richard L. Feinstein.
ENZN tiene fecha de IPO 1984-02-15, cotiza en el Other OTC, una capitalización de mercado de $4.45M.
Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford, New Jersey.
